A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Maurizio Chioccioli(Yale University), Naftali Kaminski(Yale University), Rusty L. Montgomery(The University of Texas Southwestern Medical Center), Simon R. Johnson(University of Nottingham), Maor Sauler(Yale University), Rebecca Braybrooke(National Institute for Health and Care Research), Gísli Jenkins(University College London), Linda Pestano(Miragen Therapeutics (United States)), Joseph DeIuliis(Yale University), Gauri Saini(Nottingham University Hospitals NHS Trust), Nachelle Aurelien(Yale University), Subhadeep Roy(Miragen Therapeutics (United States)), Shuizi Ding(Central South University), Brent Dickinson(Miragen Therapeutics (United States)), Steward Ian(Imperial College London), Farida Ahangari(Yale University), Guying Yu(Henan Normal University), Kevin M. Rigby(Miragen Therapeutics (United States)), Rachel Newell(Miragen Therapeutics (United States)), Jose D. Herazo‐Maya(University of South Florida)
Cited by 115
Related Papers
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis
|Journal of Clinical Investigation|2014|613
MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
|PLoS Medicine|2008|599
Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis
|PLoS Medicine|2005|500